Short-Term Oral Anticoagulation Versus Antiplatelet Therapy Following Transcatheter Left Atrial Appendage Closure
- PMID: 32772571
- DOI: 10.1161/CIRCINTERVENTIONS.120.009039
Short-Term Oral Anticoagulation Versus Antiplatelet Therapy Following Transcatheter Left Atrial Appendage Closure
Abstract
Background: The impact of antithrombotic therapy on coagulation system activation after left atrial appendage closure (LAAC) remains unknown. This study sought to compare changes in coagulation markers associated with short-term oral anticoagulation (OAC) versus antiplatelet therapy (APT) following LAAC.
Methods: Prospective study including 78 atrial fibrillation patients undergoing LAAC with the Watchman device. F1+2 (prothrombin fragment 1+2) and TAT (thrombin-antithrombin III) were assessed immediately before the procedure, and at 7, 30, and 180 days after LAAC.
Results: Forty-eight patients were discharged on APT (dual: 31, single: 17) and 30 on OAC (direct anticoagulants: 26, vitamin K antagonists: 4), with no differences in baseline-procedural characteristics between groups except for higher spontaneous echocardiography contrast in the OAC group. OAC significantly reduced coagulation activation within 7 days post-LAAC compared with APT (23% [95% CI, 5%-41%] versus 82% [95% CI, 54%-111%] increase for F1+2, P=0.007; 52% [95% CI, 15%-89%] versus 183% [95% CI, 118%-248%] increase for TAT, P=0.048), with all patients in both groups progressively returning to baseline values at 30 and 180 days. Spontaneous echocardiography contrast pre-LAAC was associated with an enhanced activation of the coagulation system post-LAAC (144 [48-192] versus 52 [24-111] nmol/L, P=0.062 for F1+2; 299 [254-390] versus 78 [19-240] ng/mL, P=0.002 for TAT). Device-related thrombosis occurred in 5 patients (6.4%), and all of them were receiving APT at the time of transesophageal echocardiography (10.2% versus 0% if OAC at the time of transesophageal echocardiography, P=0.151). Patients with device thrombosis exhibited a greater coagulation activation 7 days post-LAAC (P=0.038 and P=0.108 for F1+2 and TAT, respectively).
Conclusions: OAC (versus APT) was associated with a significant attenuation of coagulation system activation post-LAAC. Spontaneous echocardiography contrast pre-LAAC associated with enhanced coagulation activation post-LAAC, which in turn increased the risk of device thrombosis. These results highlight the urgent need for randomized trials comparing OAC versus APT post-LAAC.
Keywords: antithrombin III; atrial appendage; atrial fibrillation; prothrombin; thrombin.
Similar articles
-
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.Circ Cardiovasc Interv. 2020 Jul;13(7):e008481. doi: 10.1161/CIRCINTERVENTIONS.119.008481. Epub 2020 Jul 17. Circ Cardiovasc Interv. 2020. PMID: 32674675 Clinical Trial.
-
Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.JACC Cardiovasc Interv. 2019 Jun 10;12(11):1055-1063. doi: 10.1016/j.jcin.2019.04.004. JACC Cardiovasc Interv. 2019. PMID: 31171282
-
Changes in Coagulation and Platelet Activation Markers Following Transcatheter Left Atrial Appendage Closure.Am J Cardiol. 2017 Jul 1;120(1):87-91. doi: 10.1016/j.amjcard.2017.03.253. Epub 2017 Apr 12. Am J Cardiol. 2017. PMID: 28495432
-
Antithrombotic Therapy and Device-Related Thrombosis Following Endovascular Left Atrial Appendage Closure.JACC Cardiovasc Interv. 2019 Jun 10;12(11):1067-1076. doi: 10.1016/j.jcin.2018.11.001. Epub 2019 May 15. JACC Cardiovasc Interv. 2019. PMID: 31103535 Review.
-
Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure.BMC Cardiovasc Disord. 2024 Mar 21;24(1):175. doi: 10.1186/s12872-024-03843-w. BMC Cardiovasc Disord. 2024. PMID: 38515032 Free PMC article.
Cited by
-
Peri- and Post-procedural Anticoagulation with Left Atrial Appendage Occlusion Devices.Heart Int. 2023 Jun 21;17(1):54-59. doi: 10.17925/HI.2023.17.1.54. eCollection 2023. Heart Int. 2023. PMID: 37456348 Free PMC article. Review.
-
Left atrial appendage occlusion.EuroIntervention. 2023 Feb 6;18(13):e1038-e1065. doi: 10.4244/EIJ-D-22-00627. EuroIntervention. 2023. PMID: 36760206 Free PMC article. Review.
-
Evolution of Coagulation and Platelet Activation Markers After Transcatheter Edge-to-Edge Mitral Valve Repair.J Clin Med. 2025 Jan 27;14(3):831. doi: 10.3390/jcm14030831. J Clin Med. 2025. PMID: 39941501 Free PMC article.
-
The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure.Front Pharmacol. 2021 Sep 15;12:723905. doi: 10.3389/fphar.2021.723905. eCollection 2021. Front Pharmacol. 2021. PMID: 34603033 Free PMC article.
-
Postoperative Coagulation Changes in Patients after Epicardial Left Atrial Appendage Occlusion Varies Based on the Left Atrial Appendage Size.Diseases. 2023 Dec 29;12(1):8. doi: 10.3390/diseases12010008. Diseases. 2023. PMID: 38248359 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical